Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Reforgene Medicine

    • Home
    • Reforgene Medicine
Company Deals

Reforgene Medicine Secures Hundreds of Millions in Financing for Gene Therapy Expansion

Fineline Cube Dec 30, 2024

Reforgene Medicine, a prominent gene editing therapy company headquartered in Guangzhou, has reportedly secured hundreds...

Company Drug

Reforgene Medicine’s Gene Editing Therapy RM-101 Clears IND Hurdle for Usher Syndrome Treatment

Fineline Cube Oct 14, 2024

Reforgene Medicine, a pioneer in gene editing therapy based in Guangzhou, has secured Investigational New...

Company Deals

Reforgene Medicine Secures Pre-Series B Funding to Advance Thalassemia Gene Therapy

Fineline Cube Apr 28, 2023

Reforgene Medicine, a Guangzhou-based gene editing therapy company, has reportedly secured hundreds of millions of...

Company Drug

Reforgene Medicine RM-001 Thalassemia Gene Editing

Fineline Cube Nov 4, 2022

China-based Guangzhou Reforgene Medicine Co., Ltd’s in-house developed β-thalassemia gene editing drug RM-001 (HBG gene...

Recent updates

  • Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
  • Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures
  • Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes
  • Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod
  • TransThera Tinengotinib Cholangiocarcinoma Priority Review China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.